Stay updated with breaking news from Johnv Heymach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
David Harpole, MD, discusses key data from the first interim analysis of the AEGEAN trial, changes to the adjuvant treatment landscape that inspired the subgroup analysis of patients with EGFR mutations excluded from the intention-to-treat population, and more.
Research presented at AACR 2023 highlighted a potential new standard of care for NSCLC and other novel treatments for NSCLC and ES-SCLC.
John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.
Results from the AEGEAN trial suggest that adding perioperative durvalumab to neoadjuvant chemotherapy can improve outcomes in resectable NSCLC.
The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non–small cell lung cancer.